Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows: - product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.; - sales of services (15.9%). Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).

Employees

10,615

Sector

Advanced Medical Equipment & Technology

Calendar

2025-02-05 - Q4 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
24-12-04	141.72 $	+0.79%	752,128
24-12-03	140.60 $	-3.13%	2,084,196
24-12-02	145.15 $	+0.69%	1,524,901
24-11-29	144.15 $	-0.15%	757,872
24-11-27	144.36 $	+0.99%	1,308,844

Delayed Quote Nasdaq, December 03, 2024 at 04:00 pm EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart ILLUMINA-INC

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

140.60USD

Average target price

164.60USD

Spread / Average Target

+17.07%

Consensus

Profit revisions

Estimate revisions

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 02:45:11 2024-12-04 pm EST			5-day change	1st Jan Change
141.77 ^USD	+0.83%		-1.79%	+1.82%

12:17pm	Illumina Granted Access to Synaffix's Metal-Free Click Chemistry Technology	MT
Dec. 03	Illumina, Inc. Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference, Dec-03-2024 01:20 PM

Capitalization	22.3B 21.21B 19.76B 17.61B 31.37B 1,889B 34.44B 246B 91.09B 775B 83.78B 81.91B 3,334B	P/E ratio 2024 *	-19.5x	P/E ratio 2025 *	38.3x
Enterprise value	22.96B 21.84B 20.35B 18.14B 32.3B 1,945B 35.46B 253B 93.79B 798B 86.27B 84.34B 3,433B	EV / Sales 2024 *	5.31x	EV / Sales 2025 *	4.91x
Free-Float	79.64%	Yield 2024 *	-	Yield 2025 *	-

Illumina Granted Access to Synaffix's Metal-Free Click Chemistry Technology	06:17am	MT
Illumina, Inc. Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference, Dec-03-2024 01:20 PM	Dec. 03
EU regulators scrap merger power aimed at killer acquisitions after court veto	Nov. 29	RE
Myriad Genetics, Inc. Announces Updates to Its Agreement with Illumina Inc	Nov. 20	CI
Illumina, Inc. Presents at 6th Annual Wolfe Research Healthcare Conference 2024, Nov-20-2024 09:20 AM	Nov. 20
Illumina, Inc. Announces Expansion of TruSight Oncology Portfolio	Nov. 19	CI
Tranche Update on Illumina, Inc.'s Equity Buyback Plan announced on February 11, 2020.	Nov. 06	CI
Illumina, Inc. announces an Equity Buyback for $1,500 million worth of its shares.	Nov. 06	CI
Tranche Update on Illumina, Inc.'s Equity Buyback Plan announced on November 6, 2024.	Nov. 06	CI
UBS Increases Price Target on Illumina to $145 From $133, Maintains Neutral Rating	Nov. 05	MT
Global markets live: Palantir soars, Boeing strike ends	Nov. 05
The Election Effect	Nov. 05
Analyst recommendations: Chevron, Ebay, Palantir, Royal Caribbean, United Utilities...	Nov. 05

UBS Increases Price Target on Illumina to $145 From $133, Maintains Neutral Rating	Nov. 05	MT
Analyst recommendations: Chevron, Ebay, Palantir, Royal Caribbean, United Utilities...	Nov. 05
HSBC Upgrades Illumina to Buy From Hold, Price Target is $180	Oct. 17	MT
Analyst recommendations: Fortinet, Illumina, Kinder Morgan, Okta, Palantir...	Oct. 17
RBC Raises Price Target on Illumina to $252 From $242, Keeps Outperform Rating	Sep. 13	MT

Illumina, Inc. Stock

Equities

ILMN

US4523271090

Advanced Medical Equipment & Technology

Valuation: Illumina, Inc.

Chart: Illumina, Inc.

Latest news: Illumina, Inc.

Last Transcript: Illumina, Inc.

Analysts' recommendations: Illumina, Inc.

Press Releases: Illumina, Inc.

News in other languages: Illumina, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Illumina, Inc.

ETFs: Illumina, Inc.

Other Advanced Medical Equipment & Technology

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2	Nov. 20	AQ
Illumina announces expansion of TruSight Oncology portfolio	Nov. 19	PR
Illumina : Comprehensive Genomic Profiling leads to better patient outcomes, new joint study says	Nov. 13	PU
Illumina : Statement of Changes in Beneficial Ownership - Form 4	Nov. 07	PU
Illumina : Statement of Changes in Beneficial Ownership - Form 4	Nov. 07	PU

And the winner is…	Nov. 05
En Direct des Marchés : Carrefour veut devenir sexy, Palantir flambe, fin de grève chez Boeing	Nov. 05
La semaine la plus importante de l'année ?	Nov. 04
En Direct des Marchés : du rififi chez Schneider, Nvidia dans le DJIA, le trésor de Berkshire	Nov. 04
McDonald´s y dos valores más a tener muy en cuenta este jueves en Wall Streer	Oct. 03

1 day	-3.13%
1 week	-1.64%
Current month	-2.46%
1 month	-6.12%
3 months	+7.94%
6 months	+36.02%
Current year	+0.98%

Director	Title	Age	Since
Jacob Thaysen CEO	Chief Executive Officer	49	2023-09-24
Ankur Dhingra DFI	Director of Finance/CFO	48	2024-04-14
Steven Barnard CTO	Chief Tech/Sci/R&D Officer	-	2023-08-08

Manager	Title	Age	Since
Robert Epstein BRD	Director/Board Member	58	2012-11-28
Frances Arnold BRD	Director/Board Member	67	2016-01-27
Philip Schiller BRD	Director/Board Member	63	2016-07-27

Name	Weight	AuM	1st Jan change	Investor Rating
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD	4.11%	2 M€	-.--%
FIRST TRUST NYSE ARCA BIOTECHNOLOGY ETF - CAD	3.62%	1 M€	-.--%	-
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD	3.11%	0 M€	0.00%	-
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD	3.03%	0 M€	0.00%	-
KELLY STRATEGIC CRISPR & GENE EDITING TECHNOLOGY ETF - USD	1.77%	2 M€	-25.75%

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
ILLUMINA, INC.	-3.13%	-1.64%	+28.06%	-59.51%	22.3B
THERMO FISHER SCIENTIFIC INC.	+0.84%	+4.18%	+7.72%	-15.99%	204B
INTUITIVE SURGICAL, INC.	-0.21%	-0.07%	+71.86%	+68.43%	193B
DANAHER CORPORATION	-0.17%	+1.81%	+7.78%	-23.03%	174B
BOSTON SCIENTIFIC CORPORATION	+0.04%	+0.29%	+61.15%	+129.27%	133B
SIEMENS HEALTHINEERS AG	+0.17%	+1.69%	-1.07%	-18.70%	60.83B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.95%	-2.20%	-10.13%	-26.14%	43.28B
EDWARDS LIFESCIENCES CORPORATION	-0.47%	-1.89%	+2.69%	-35.29%	41.4B
AGILENT TECHNOLOGIES, INC.	-0.21%	+3.65%	+8.15%	-6.73%	39.72B
GE HEALTHCARE TECHNOLOGIES INC.	-0.61%	+0.07%	+18.96%	-	37.72B
Average	-0.47%	+0.47%	+19.52%	+1.37%	94.99B
Weighted average by Cap.	-0.05%	+1.21%	+27.61%	+19.56%

	2024 *	2025 *
Net sales	4.32B 4.11B 3.83B 3.41B 6.08B 366B 6.67B 47.6B 17.65B 150B 16.23B 15.87B 646B	4.5B 4.28B 3.99B 3.55B 6.33B 381B 6.95B 49.58B 18.38B 156B 16.91B 16.53B 673B
Net income	-1.13B -1.08B -1B -893M -1.59B -95.8B -1.75B -12.46B -4.62B -39.28B -4.25B -4.15B -169B	515M 490M 457M 407M 725M 43.66B 796M 5.68B 2.11B 17.91B 1.94B 1.89B 77.07B
Net Debt	662M 630M 587M 523M 932M 56.11B 1.02B 7.3B 2.71B 23.01B 2.49B 2.43B 99.04B	-215M -204M -190M -170M -302M -18.19B -332M -2.37B -877M -7.46B -807M -789M -32.1B